Aging
Navigate
Submit an Article
Research Paper|Volume 14, Issue 6|pp. 2868–2879
TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types
Back to articleFigure 1(1 of 4)
100%
Figure 1
Figure 1.Prevalence of TP53/BRAF mutations in pan-cancer.
Figure 1 — TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types | Aging